Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer
Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.
CancerNetwork® spoke with Jun Gong, MD, a practicing medical oncologist who specializes in the treatment of genitourinary cancers at Cedars-Sinai Medical Center, regarding a perspective piece he wrote titled, “Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer.”
Gong’s perspective analyzes and builds upon a study featured in the January issue of ONCOLOGY® titled, “Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017.”
In this conversation, Gong provided an overview of the research and touched on some of the clinically relevant findings. He then expanded on the use of cisplatin-based chemotherapy in an aging population, how age fits into the treatment equation, and where research should focus moving forward in muscle-invasive bladder cancer.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Sacituzumab Govitecan Combo Shows Encouraging Responses in Bladder Cancer
February 15th 2024Investigators report clinical benefit with sacituzumab govitecan plus pembrolizumab across all prespecified patient subgroups with metastatic urothelial cancer in cohort 3 of the phase 2 TROPHY-U-01 trial.
